Issue Special Issue 1/2010
Content (12 Articles)
A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection
Josephine Mauskopf, Lieven Annemans, Andrew M. Hill, Erik Smets
Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era
Mark A. Boyd, Andrew M. Hill
The Impact of Disease Stage on Direct Medical Costs of HIV Management
Adrian Levy, Karissa Johnston, Lieven Annemans, Andrea Tramarin, Julio Montaner
Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden
Ola Ghatnekar, Catharina Hjortsberg, Magnus Gisslén, Stefan Lindbäck, Mickael Löthgren
The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France
Xavier Colin, Antoine Lafuma, Dominique Costagliola, Jean-Marie Lang, Pascal Guillon
Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients
Andrew M. Hill, Bonaventura Clotet, Margaret Johnson, Matthias Stoll, Nicholas Bellos, Erik Smets
Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA
Josephine Mauskopf, Anita Brogan, Silas Martin, Erik Smets
Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK
Karen Moeremans, Lieven Annemans, Mickael Löthgren, Gabriele Allegri, Veronique Wyffels, Lindsay Hemmet, Karin Caekelbergh, Erik Smets
US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial
Anita Brogan, Josephine Mauskopf, Sandra E. Talbird, Erik Smets
Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK
Karen Moeremans, Lindsay Hemmett, Jonas Hjelmgren, Gabriele Allegri, Erik Smets
Predicting Direct Costs of HIV Care During the First Year of Darunavir-Based Highly Active Antiretroviral Therapy Using CD4 Cell Counts
Andrew M. Hill, Kelly Gebo, Lindsay Hemmett, Mickael Löthgren, Gabriele Allegri, Erik Smets
Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France
Xavier Colin, Antoine Lafuma, Dominique Costagliola, Erik Smets, Josephine Mauskopf, Pascal Guillon